The clinical effects of vasopressin receptor antagonists in heart failure

Cleveland Clinic Journal of Medicine

Volumn 73, Issue SUPPL.2, 2006, Pages

  Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864831559     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.Suppl_2.S24     Document Type: Article

References (15)

1. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791.
2. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112:3958-3968.
3. Fonarow GC, ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4(Suppl 7):S21-S30.
4. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96(6A):11G-17G.
5. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 2005; 111:2454-2460.
6. Gheorghiade M, Stough WG, O'Connor CM, et al. Serum sodium concentration and mortality in patients admitted with heart failure: an analysis of OPTIMIZEHF. J Card Fail 2005; 11(Suppl):Abstract 348.
7. Gheorghiade M, Adams K, O'Connor C, et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF). J Am Coll Cardiol 2005; 45(Suppl A):Abstract 1075-148.
8. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001; 104:2417-2423.
9. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290:F273-F278.
10. Udelson JE, Orlandi C, O'Brien T, Sequeira R, Ouyang J, Konstam MA. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination. J Am Coll Cardiol 2002; 39(Suppl):156A. Abstract 840-4.
11. Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97:1064-1067.
12. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107:2690-2696.
13. Udelson JE, McGrew F, Flores E, et al. Effects of the vasopressin V2 receptor antagonist, tolvaptan, on the long-term progression of left ventricular dilatation in patients with heart failure. Circulation 2005; 112(Suppl II):II-504. Abstract 2415.
14. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963-1971.
15. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11:260-269.